frontotemporal dementia
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Diagnosed with non-genetic Frontotemporal Dementia, diagnosed by a physician at the Alzheimercentrum Amsterdam (AmsterdamUMC locatie VUmc and; Registered at the Dutch Brain Bank (Nederlandse Hersenbank) to donate their brains when they decease - Diagnosed with genetic frontotemporal dementia
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Contra-indication to perform a skin biopsy (known cause for prolonged bleeding, high risk of infection) - No cerebral spine fluid biomaterial or biomarker results available to exclude co-existing Alzheimer pathology
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collect iPSC derived neurons from FTD patients for further proteomics and cellomics studies. Using proteomics, a signature protein profile will be ascertained for genetic and sporadic FTD cases. With cellomics, effects of protein regulation in FTD can be investigated on the cellular functional level. | — |
Secondary
| Measure | Time frame |
|---|---|
| Genetic testing for known causal FTD genes in sporadic patients will help affirm the sporadic nature of FTD symptoms in these patients. In case a mutation is identified, the patient will be notified if there is a treatment available and if the patient consented to receiving this information. Neuropathological reports from the NBB on the post-mortem state of FTD brain tissue will help us to better subcategorize sporadic FTD patients, and to eliminate confounding pathology or disease. | — |
Countries
Netherlands
Outcome results
None listed